5 results about "P2Y12" patented technology

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, alone or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts (“TEVGs”) in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The invention discloses an application of a P2Y12 inhibitor in a medicine for treating osteoarthritis, aims to provide a new medicine for treating osteoarthritis, and relates to the application of the P2Y12 inhibitor in treating osteoarthritis, and the P2Y12 inhibitor can be used for treating osteoarthritis. The method can further deepen the understanding of the mechanism of promoting the OA progress by the HNP1, and opens up the possibility for a novel intervention strategy of the OA. The targeting HNP1-P2Y12-NF-kappa B / IFIL44 axis may provide a new way for inhibiting COL2 degradation and cartilage destruction, and fills the blank in OA treatment.

The present invention provides a pharmaceutical composition comprising ticagrelor for use in the treatment, reduction, or prevention of ischemic events in a patient who has undergone percutaneous coronary intervention (PCI), comprising the step of administering an effective amount of ticagrelor to the patient to initiate or maintain P2Y12 inhibition during percutaneous coronary intervention (PCI); wherein the pharmaceutical composition is an aqueous ticagrelor solution comprising a solubilizing agent in an effective amount for solubilizing ticagrelor; wherein the pharmaceutical composition is provided by intravenous administration, and the effective amount of ticagrelor is administered intravenously.

The present invention provides a pharmaceutical composition comprising ticagrelor for treating, reducing, or preventing ischemic events in patients undergoing percutaneous coronary intervention (PCI), comprising administering an effective amount of ticagrelor to the patient to initiate or maintain P2Y12 inhibition during PCI, characterized in that the pharmaceutical composition is an aqueous solution of ticagrelor comprising an effective amount of a solubilizer for solubilizing ticagrelor, and the pharmaceutical composition is provided for intravenous administration; wherein the effective amount of ticagrelor is administered intravenously.